Shruti Patel, MD

All Publications

• Racial disparities in molecular testing among patients with early-onset metastatic pancreatic ductal adenocarcinoma. Kirmani, N., Abdusumad, R., Balakrishnan, A., Trinh, Q., Saptono, C., Patel, S. LIPPINCOTT WILLIAMS & WILKINS. 2026: e13752

  View details for DOI 10.1200/JCO.2026.44.16_suppl.e13752

  View details for Web of Science ID 001780466400039

• Sex-based differences in metastasis among patients with early-onset pancreatic ductal adenocarcinoma. Kirmani, N., Abdusumad, R., Balakrishnan, A., Trinh, Q., Saptono, C., Patel, S. LIPPINCOTT WILLIAMS & WILKINS. 2026: e16423

  View details for DOI 10.1200/JCO.2026.44.16_suppl.e16423

  View details for Web of Science ID 001780577000031

• KRAS Variant Frequency and Colorectal Cancer-Specific Survival by Race and Ethnicity. JAMA network open Rodriguez, G. M., Aljehani, M., DePuy, D., Patel, S. R., Fisher, G. A., Lin, A. Y. 2026; 9 (3): e261585

  Abstract

  Colorectal cancer is the third most commonly diagnosed cancer and the third leading cause of cancer-associated deaths in the US. Hispanic and non-Hispanic Black patients experience higher colorectal cancer mortality rates compared with non-Hispanic White patients. More data are needed to understand the role of cancer biology in colorectal cancer survival disparities among racial and ethnic minority groups.To evaluate racial and ethnic differences in KRAS variant frequency and the association of presence of a KRAS variant with colorectal cancer-specific survival.This population-based cross-sectional study used data from the Surveillance, Epidemiology, and End Results Program and included patients diagnosed with colorectal cancer from 2010 through 2015, with follow-up through December 31, 2018. Data were analyzed between December 2023 and August 2024.Racial and ethnic differences in KRAS variant frequency.Outcomes of interest were cumulative incidence of colorectal cancer-specific death, assessed using cumulative incidence functions, and subdistribution hazard ratio (sHR) for colorectal cancer-specific death, assessed using Fine-Gray regression models.A total of 21 354 patients (mean [SD] age at diagnosis, 62.54 [13.78] years; 9653 females [45.2%]; median [IQR] follow-up, 2.67 [1.25-4.17] years) were included in the analysis, including 1680 Asian or Pacific Islander patients (7.8%), 2459 Hispanic patients (11.5%), 2761 non-Hispanic Black patients (12.9%), and 14 454 non-Hispanic White patients (67.7%). Hispanic patients and non-Hispanic Black patients had higher KRAS variant frequencies than non-Hispanic Asian or Pacific Islander patients and non-Hispanic White patients (44.2% and 48.3% vs 37.5% and 39.3%, respectively). Among patients with KRAS wild-type tumors, the unadjusted cumulative incidence of colorectal cancer-specific death was highest for Hispanic patients (59.5%; 95% CI, 55.4%-63.3%; P < .001); among patients with KRAS variant tumors, colorectal cancer-specific death was highest for non-Hispanic Black patients (67.3%; 95% CI, 63.3%-70.9%; P < .001). Among patients with KRAS wild-type tumors, Hispanic patients showed a significantly increased risk of colorectal cancer-specific death (sHR, 1.11; 95% CI, 1.01-1.22; P = .03). Among patients with KRAS variant tumors, non-Hispanic Black patients had a significantly increased risk of colorectal cancer-specific death (sHR, 1.18; 95% CI, 1.07-1.29; P < .001).In this cross-sectional study of patients with colorectal cancer, Hispanic patients and non-Hispanic Black patients had higher KRAS variant prevalence than non-Hispanic White patients. Among patients with a KRAS variant, non-Hispanic Black patients had worse cause-specific survival than non-Hispanic White patients. Among patients with wild-type KRAS, Hispanic patients had worse survival compared with non-Hispanic White patients. These findings highlight the need for further research on racial and ethnic differences in KRAS-related outcomes.

  View details for DOI 10.1001/jamanetworkopen.2026.1585

  View details for PubMedID 41817523

• Immunotherapy Efficacy in Mismatch Repair-Proficient Colorectal Cancer Patients With and Without Liver Metastases. Journal of clinical oncology : official journal of the American Society of Clinical Oncology Beiter, E. R., Patel, S. R., Chen, C. T. 2025: JCO2501044

  View details for DOI 10.1200/JCO-25-01044

  View details for PubMedID 40934442

• Invisible in the Metrics of Academic Oncology. JCO oncology practice Patel, S. R., Graff, S. L. 2025: OP2500283

  View details for DOI 10.1200/OP-25-00283

  View details for PubMedID 40540705

• Redefining Available Therapy in Oncology Accelerated Approval Decisions. Journal of clinical oncology : official journal of the American Society of Clinical Oncology Patel, S. R., Ramachandran, M., Ai, A., Chen, C. T. 2024: JCO2400892

  Abstract

  When weighing rapid approval for follow-on drugs, should @FDAOncology recognize the drugs that came before?

  View details for DOI 10.1200/JCO.24.00892

  View details for PubMedID 39454117

• Lung Cancer in Women: The Past, Present, and Future. Clinical lung cancer Florez, N., Kiel, L., Riano, I., Patel, S., DeCarli, K., Dhawan, N., Franco, I., Odai-Afotey, A., Meza, K., Swami, N., Patel, J., Sequist, L. V. 2023

  Abstract

  Lung cancer is the leading cause of cancer death for women in multiple countries including the United States. Women are exposed to unique risk factors that remain largely understudied such as indoor pollution, second-hand tobacco exposure, biological differences, gender differences in tolerability and response to therapy in lung cancer, and societal gender roles, that create distinct survivorship needs. Women continue to lack representation in lung cancer clinical trials and are typically treated with data generated from majority male patient study populations, which may be inappropriate to extrapolate and generalize to females. Current lung cancer treatment and screening guidelines do not incorporate sex-specific differences and physicians also often do not account for gender differences when choosing treatments or discussing survivorship needs. To best provide targeted treatment approaches, greater representation of women in lung cancer clinical trials and further research is necessary. Clinicians should understand the unique factors and consequences associated with lung cancer in women; thus, a holistic approach that acknowledges environmental and societal factors is necessary.

  View details for DOI 10.1016/j.cllc.2023.10.007

  View details for PubMedID 37940410

• Small Cell Lung Cancer: Emerging Targets and Strategies for Precision Therapy. Cancers Patel, S. R., Das, M. 2023; 15 (16)

  Abstract

  Small cell lung cancer is an aggressive subtype of lung cancer with limited treatment options. Precision medicine has revolutionized cancer treatment for many tumor types but progress in SCLC has been slower due to the lack of targetable biomarkers. This review article provides an overview of emerging strategies for precision therapy in SCLC. Targeted therapies include targeted kinase inhibitors, monoclonal antibodies, angiogenesis inhibitors, antibody-drug conjugates, PARP inhibitors, and epigenetic modulators. Angiogenesis inhibitors and DNA-damaging agents, such as PARP and ATR inhibitors, have been explored in SCLC with limited success to date although trials are ongoing. The potential of targeting DLL3, a NOTCH ligand, through antibody-drug conjugates, bispecific T-cell engagers, and CAR T-cell therapy, has opened up new therapeutic options moving forward. Additionally, new research in epigenetic therapeutics in reversing transcriptional repression, modulating anti-tumor immunity, and utilizing antibody-drug conjugates to target cell surface-specific targets in SCLC are also being investigated. While progress in precision therapy for SCLC has been challenging, recent advancements provide optimism for improved treatment outcomes. However, several challenges remain and will need to be addressed, including drug resistance and tumor heterogeneity. Further research and biomarker-selected clinical trials are necessary to develop effective precision therapies for SCLC patients.

  View details for DOI 10.3390/cancers15164016

  View details for PubMedID 37627044

• Adjuvant osimertinib for resected EGFR-mutated non-small cell lung cancer: a game-changer? Translational lung cancer research Patel, S. R., Neal, J. W. 2023; 12 (7): 1631-1635

  View details for DOI 10.21037/tlcr-23-273

  View details for PubMedID 37577327

  View details for PubMedCentralID PMC10413020

• Enhancing Patient Retention in Clinical Trials-Strategies for Success. JAMA oncology Idossa, D., Patel, S., Florez, N. 2023

  View details for DOI 10.1001/jamaoncol.2023.1341

  View details for PubMedID 37347478

• Adjuvant osimertinib for resected EGFR-mutated non-small cell lung cancer: a game-changer? TRANSLATIONAL LUNG CANCER RESEARCH Patel, S. R., Neal, J. W. 2023

  View details for DOI 10.21037/tlcr-23-273

  View details for Web of Science ID 001015487200001

• What is your preferred language? Evaluating equal access to oncology clinical studies for non-English-speaking participants Idossa, D., Manana, A., Horiguchi, M., Suero-Abreu, G., Franco, I., Borrero, M., Patel, S., Dhawan, N., Florez, N. LIPPINCOTT WILLIAMS & WILKINS. 2023

  View details for Web of Science ID 001053772003267

• Race/Ethnicity and Gender Representation in Hematology and Oncology Editorial Boards: What is the State of Diversity? The oncologist Patel, S. R., Riano, I., Abuali, I., Ai, A., Geiger, G., Pimienta, J., Ramirez Roggio, A., Dhawan, N., Dizman, N., Lizette Salinas, A., Pomares-Millan, H., Florez, N. 2023

  Abstract

  Women and underrepresented groups in medicine hold few academic leadership positions in the field of hematology/oncology. In this study, we assessed gender and race/ethnicity representation in editorial board positions in hematology/oncology journals.Editorial leadership board members from 60 major journals in hematology and oncology were reviewed; 54 journals were included in the final analysis. Gender and race/ethnicity were determined based on publicly available data for Editor-in-Chief (EiC) and Second-in-Command (SiC) (including deputy, senior, or associate editors). Descriptive statistics and chi-squared were estimated. In the second phase of the study, editors were emailed a 4-item survey to self-identify their demographics.Out of 793 editorial board members, 72.6% were men and 27.4% were women. Editorial leadership were non-Hispanic white (71.1%) with Asian editorial board members representing the second largest majority at 22.5%. Women comprised only 15.9% of the EiC positions (90% White and 10% Asian). Women were about half as likely to be in the EiC position compared with men [pOR 0.47 (95% CI, 0.23-0.95, P = .03)]. Women represented 28.3% of SiC editorial positions. Surgical oncology had the lowest female representation at 2.3%.Women and minorities are significantly underrepresented in leadership roles on Editorial Boards in hematology/oncology journals. Importantly, the representation of minority women physicians in EiC positions is at an inexorable zero.

  View details for DOI 10.1093/oncolo/oyad103

  View details for PubMedID 37119268

• Disparities in cancer care-A call to action. Cancer cell Abuali, I., Patel, S., Kiel, L., Meza, K., Florez, N. 2023; 41 (1): 1-4

  Abstract

  Disparities in cancer care disproportionately impact minority groups, members of which face challenges in accessing high-quality cancer care, remain underrepresented in clinical trials, and experience significant financial toxicity and discrimination during their cancer journey. Diversifying our workforce, improving access to trials, and allocating research funding for equitable initiatives should be prioritized.

  View details for DOI 10.1016/j.ccell.2022.11.003

  View details for PubMedID 36626866

• Inequity in care delivery in cardio-oncology: dissecting disparities in underrepresented populations. Frontiers in oncology Patel, S. R., Suero-Abreu, G. A., Ai, A., Ramachandran, M. K., Meza, K., Florez, N. 2023; 13: 1124447

  Abstract

  It is well known that patients with cancer have a significantly higher cardiovascular mortality risk than the general population. Cardio-oncology has emerged to focus on these issues including risk reduction, detection, monitoring, and treatment of cardiovascular disease or complications in patients with cancer. The rapid advances in early detection and drug development in oncology, along with socioeconomic differences, racial inequities, lack of support, and barriers to accessing quality medical care, have created disparities in various marginalized populations. In this review, we will discuss the factors contributing to disparities in cardio-oncologic care in distinct populations, including Hispanic/Latinx, Black, Asian and Pacific Islander, indigenous populations, sex and gender minorities, and immigrants. Some factors that contribute to differences in outcomes in cardio-oncology include the prevalence of cancer screening rates, genetic cardiac/oncologic risk factors, cultural stressors, tobacco exposure rates, and physical inactivity. We will also discuss the barriers to cardio-oncologic care in these communities from the racial and socioeconomic context. Appropriate and timely cardiovascular and cancer care in minority groups is a critical component in addressing these disparities, and there need to be urgent efforts to address this widening gap.

  View details for DOI 10.3389/fonc.2023.1124447

  View details for PubMedID 37361603

• Optimal timing and interval of imaging for metastatic breast cancer. Patel, S., Itakura, H., Sledge, G. W. LIPPINCOTT WILLIAMS & WILKINS. 2022

  View details for Web of Science ID 000863680300340

• Clinicopathological characteristics and prognostic significance of HDAC11 protein expression in non-small cell lung cancer: a retrospective study. Translational lung cancer research Lu, D., Ma, Z., Huang, D., Zhang, J., Li, J., Zhi, P., Zhang, L., Feng, Y., Ge, X., Zhai, J., Jiang, M., Zhou, X., Simone, C. B., Neal, J. W., Patel, S. R., Yan, X., Hu, Y., Wang, J. 2022; 11 (6): 1119-1131

  Abstract

  Background: Although the prognosis of non-small cell lung cancer (NSCLC) can be assessed based on pathological type, disease stage and inflammatory indicators, the prognostic scoring model of NSCLC still needs to improve. HDAC11 is associated with poor prognosis of partial tumors, but its prognostic relationship with NSCLC is poorly understood. In this study, the role of HDAC11 in NSCLC was studied to evaluate relationship with disease prognosis and potential therapeutic target.Methods: The clinicopathological and paracancerous tissues of patients with NSCLC primarily diagnosed in Tangdu Hospital from 2009 to 2013 were collected. Follow-up of patients were made every three months and the last follow-up period was December 2018. The expression of HDAC11 was assessed by immunohistochemistry (IHC). Then, weighted gene co-expression network analysis (WGCNA) was used to analyze the relationship between HDAC11 expression and the prognosis of lung adenocarcinoma (LUAD) patients. Gene Ontology (GO) and Kyoto Encyclopedia of Genes and Genomes (KEGG) pathway enrichment analysis. Kaplan-Meier plotter database was used to verify the connection between hub genes and tumor stage and prognosis. We accessed the relationship between HDAC11 expression and clinicopathological features, and impact on the prognosis.Results: The study assessed 326 patients with NSCLC. Compared with adjacent tissues, HDAC11 expression was upregulated (HR =1.503, 95% CI: 1.172 to 1.927, P=0.001). Kaplan-Meier survival analyses showed that HDAC11 expression was closely related to OS of NSCLC patients (P=0.0011). Univariate and multivariate analyses showed that the independent risk factors of OS were clinical stage, HDAC11 expression, and HDAC11 differentiation (all P≤0.001). HDAC11 was significantly associated with prognosis in LUAD. A total of 1,174 differential genes and WGCNA were obtained to construct a co-expression network in LUAD. The GO and KEGG pathway enrichment analyses showed the relevance with staphylococcus aureus infection, NOD-like receptor signaling pathway, and others. The results of LUAD survival analysis showed that HDAC11-related genes NKX2-5 and FABP7 were significantly associated with LUAD prognosis.Conclusions: The high expression of HDAC11 is related to the poor prognosis of LUAD, and it is expected to become a therapeutic target and prognostic evaluation therapy for LUAD in the future. However, the relevant results need to be further studied and verified.

  View details for DOI 10.21037/tlcr-22-403

  View details for PubMedID 35832445

• Disparities in Cardio-Oncology Care in the Hispanic/Latinx Population. JCO oncology practice Suero-Abreu, G. A., Patel, S., Duma, N. 2022; 18 (5): 404-409

  View details for DOI 10.1200/OP.22.00045

  View details for PubMedID 35544659

• N-Terminal Pro Brain Natriuretic Peptide, sST2, and Galectin-3 Levels in Breast Cancer Survivors. Journal of clinical medicine Patel, S. R., Herrmann, J., Vierkant, R. A., Olson, J. E., Couch, F. J., Hazim, A., Sloan, J. A., Loprinzi, C. L., Ruddy, K. J. 2021; 10 (15)

  Abstract

  NT-proBNP, soluble ST2 (sST2), and galectin-3 are biomarkers of cardiac dysfunction that have been proposed as identifiers of patients experiencing asymptomatic cardiac dysfunction after anthracycline-based chemotherapy. This study aimed to compare the proportion of breast cancer (BC) survivors with elevated serum levels of these three putative biomarkers by prior receipt of anthracycline (yes vs. no). Five-hundred-eighty survivors of BC who had received anthracycline-based chemotherapy were matched by age and time between diagnosis and serum storage to 580 who had not. Cardiac biomarker levels were analyzed using immunoassays. Analyses were carried out using linear and logistic regression models. Anthracycline recipients had higher values of NT-proBNP than non-recipients (mean 116.0 ng/L vs. 97.0 ng/L, respectively; p < 0.001). Values for ST2 and galectin-3 did not significantly differ by receipt of anthracycline. After further adjustment for age at breast cancer diagnosis, ethnicity, and receipt of trastuzumab, associations between receipt of anthracycline and higher NT-proBNP persisted (p < 0.001), showing that NT-proBNP may be a biomarker of cardiovascular toxicity after receipt of anthracycline-based chemotherapy. Further research to assess the clinical utility of NT-proBNP testing after receipt of anthracycline is recommended. sST2 and galectin-3 do not appear to differentiate between anthracycline recipients and non-recipients amongst breast cancer survivors.

  View details for DOI 10.3390/jcm10153313

  View details for PubMedID 34362097

  View details for PubMedCentralID PMC8346981

• The Matilda Effect: Underrecognition of Women in Hematology and Oncology Awards ONCOLOGIST Patel, S. R., St. Pierre, F., Velazquez, A. I., Ananth, S., Durani, U., Anampa-Guzman, A., Castillo, K., Dhawan, N., Oxentenko, A. S., Duma, N. 2021

  Abstract

  The proportion of women in the field of hematology and oncology (H&O) has increased over recent decades, but the representation of women in leadership positions remains poor. In an effort to close the gender gap in academia, it is important to report on such inequities in hopes to close these gaps and improve career development.We conducted a retrospective, observational study of published award recipients from 1994 to 2019 from the seven major H&O societies in the world. Gender was determined based on publicly available data. The χ2 and Cochran-Armitage tests were used for data analysis.Of the 1,642 awardees over the past 26 years, 915 met inclusion criteria. Award recipients were overwhelmingly men (77.9%) and non-Hispanic White (84.7%). Women awardees received 30.3% of the humanistic and education-related awards, whereas only receiving 16.0% of basic science awards (p < .01). Women represent 35.6% of all hematologists and oncologists but only received 24.0% of awards given to these physicians (p = .004). Black, Hispanic, and Asian awardees represented 3.7%, 3.3%, and 6.8% of the total awardees, respectively.From 1994 to 2019, women were less likely to receive recognition awards from the seven major H&O societies studied compared with men. We also observed a considerably low proportion of minority awardees across all oncology subspecialties. Further studies examining how selection criteria favor either gender would be warranted in order to achieve equal representation in academic awards.In this study, women and minority groups were found to be underrepresented amongst award recipients. Significant disparities were seen in disciplines that have been historically male predominant, such as basic sciences. As awards on an international level enhance academic resumes and assist with career advancement, it is important that awards are being given in an equitable manner. First steps to promote diversity and inclusion in academic medicine is reporting of gender and racial disparities in various areas of academia.

  View details for DOI 10.1002/onco.13871

  View details for Web of Science ID 000671160700001

  View details for PubMedID 34157172

• Evidence to Date: Evaluating Pembrolizumab in the Treatment of Extensive-Stage Small-Cell Lung Cancer. Clinics and practice Riano, I., Patel, S. R., Liu, S. V., Duma, N. 2021; 11 (3): 441-454

  Abstract

  Small-cell lung cancer (SCLC) is an aggressive subtype of lung cancer characterized by a rapid initial response and early development of resistance to systemic therapy and radiation. The management of SCLC significantly changed for the first time in decades with the introduction of immune checkpoint inhibitors. Pembrolizumab, a humanized IgG4 isotype antibody, targets the programmed cell death protein 1 (PD-1) pathway to restore anti-tumor immunity. Prospective trials of pembrolizumab in patients with previously treated SCLC showed significant durability of responses. These results led to the U.S. Food and Drug Administration (FDA) granting pembrolizumab accelerated approval as second- or third-line monotherapy for patients with extensive-stage (ES) SCLC. In a recent clinical trial that included patients with previously untreated ES-SCLC, pembrolizumab in combination with platinum/etoposide met its progression-free survival endpoint, but overall survival (OS) did not cross the threshold for superiority. With the therapeutic landscape for SCLC rapidly evolving, we review prior experience and future directions of pembrolizumab in ES-SCLC.

  View details for DOI 10.3390/clinpract11030059

  View details for PubMedID 34287275

  View details for PubMedCentralID PMC8293071

• Stress, Resilience, and Coping of Healthcare Workers during the COVID-19 Pandemic. Journal of primary care & community health Croghan, I. T., Chesak, S. S., Adusumalli, J., Fischer, K. M., Beck, E. W., Patel, S. R., Ghosh, K., Schroeder, D. R., Bhagra, A. 2021; 12: 21501327211008448

  Abstract

  To estimate the health care workers (HCWs) self-reported stress, resilience, and coping during the COVID-19 pandemic, and to determine inter-professional differences.An email survey was sent to 474 HCW at a Midwestern HealthCare facility between April 9, 2020 and April 30, 2020. A total of 311 (65.6%) responses were received by May 31, 2020. The survey utilized 3 validated instruments: Perceived Stress Scale (PSS), Brief Resilience Scale (BRS), Brief Resilience Coping Scale (BRCS).Of the 311 responses, 302 were evaluated: 97 from nonmedical staff with patient contact (NMPC); 86 from nonmedical staff with no patient contact (NMNPC); 62 from medical doctors (MD), physician assistants (PA) and nurse practitioners (NP); and 57 from nurses. Significant differences were noted across job categories for stress and resilience, with nurses reporting highest PSS scores (effect estimates: -2.72, P = .009 for NMNPC; -2.50, P = .015 for NMPC; -3.21, P = .006 for MD/NP/PA respectively), and MD/NP/PA group with highest BRS scores: nurses (-0.31, P = .02); NMPC (-0.3333, P = .01); and NMNPC (-0.2828, P = .02). Younger personnel had higher stress (-1.59 per decade of age, P < .01) and more resilience (0.11 per decade of age, P = .002).These self-reported data indicate that MD/NP/PA had the highest resilience scores and the nurses had highest stress levels. Efforts are warranted to include all HCWs in systematic stress mitigating interventions with particular attention to understand specific factors contributing to stress for the nursing team.

  View details for DOI 10.1177/21501327211008448

  View details for PubMedID 33834900

  View details for PubMedCentralID PMC8040550

• Metastatic Colon Cancer Presenting With Immune-mediated Necrotizing Myopathy. Clinical colorectal cancer Patel, S. R., Saliba, A. N., Steel, S., Liewluck, T., Mahipal, A. 2021; 20 (1): e71-e73

  View details for DOI 10.1016/j.clcc.2020.08.005

  View details for PubMedID 32988745

• 57-Year-Old Woman With Weakness and Word-Finding Difficulties. Mayo Clinic proceedings Patel, S., Sanborn, D., Issa, M. 2021; 96 (2): 473-477

  View details for DOI 10.1016/j.mayocp.2020.06.064

  View details for PubMedID 33549264

• Cardiovascular Health during and after Cancer Therapy. Cancers Ruddy, K. J., Patel, S. R., Higgins, A. S., Armenian, S. H., Herrmann, J. 2020; 12 (12)

  Abstract

  Certain cancer treatments have been linked to specific cardiovascular toxicities, including (but not limited to) cardiomyopathy, atrial fibrillation, arterial hypertension, and myocarditis. Radiation, anthracyclines, human epidermal growth factor receptor 2 (Her2)-directed therapies, fluoropyrimidines, platinums, tyrosine kinase inhibitors and proteasome inhibitors, immune checkpoint inhibitors, and chimeric antigen-presenting (CAR)-T cell therapy can all cause cardiovascular side effects. Management of cardiovascular dysfunction that occurs during cancer therapy often requires temporary or permanent cessation of the risk-potentiating anti-neoplastic drug as well as optimization of medical management from a cardiovascular standpoint. Stem cell or bone marrow transplant recipients face unique cardiovascular challenges, as do patients at extremes of age.

  View details for DOI 10.3390/cancers12123737

  View details for PubMedID 33322622

  View details for PubMedCentralID PMC7763346

• An integrated and intergenerational community response to promote holistic wellbeing during the COVID-19 pandemic. Explore (New York, N.Y.) Bhagra, O., Patel, S. R., Chon, T. Y. 2020; 16 (5): 283-285

  View details for DOI 10.1016/j.explore.2020.05.018

  View details for PubMedID 32690384

  View details for PubMedCentralID PMC7331504

• The Matilda effect: Under-representation of women in hematology and oncology awards. Patel, S. R., St-Pierre, F., Manana, A., Ananth, S., Durani, U., Anampa-Guzman, A., Castillo, K., Dhawan, N., Ruddy, K., Oxentenko, A. S., Duma, N. LIPPINCOTT WILLIAMS & WILKINS. 2020

  View details for Web of Science ID 000560368300330

• Peripheral endothelial function changes during HER2-directed therapy differ based on whether or not a patient receives anthracycline. Hazim, A., Nhola, L. F., Villarraga, H. R., Patel, S. R., Sandhu, N., Lerman, A., Loprinzi, C. L., Ruddy, K., Herrmann, J. LIPPINCOTT WILLIAMS & WILKINS. 2020

  View details for Web of Science ID 000560368300213

• Osimertinib-Induced Cardiomyopathy. JACC. Case reports Patel, S. R., Brown, S. N., Kubusek, J. E., Mansfield, A. S., Duma, N. 2020; 2 (4): 641-645

  Abstract

  Osimertinib is the preferred treatment in patients with metastatic non-small cell lung cancer with epidermal growth factor receptor mutations. We report a case series of acute cardiomyopathy with heart failure exacerbation during osimertinib treatment. We suggest that cardiotoxicity from osimertinib is reversible and occurs at a dose of 80 mg/day. (Level of Difficulty: Intermediate.).

  View details for DOI 10.1016/j.jaccas.2019.12.038

  View details for PubMedID 34317311

  View details for PubMedCentralID PMC8298525

• Onset, duration, and clinical impact of immune-related adverse events in Hodgkin lymphoma Higgins, A., Richter, M. D., Patel, S., McCullough, K., Habermann, T., Ansell, S. M., Thompson, C. A., Bennani, N., Thanarajasingam, U., Thanarajasingam, G. AMER SOC CLINICAL ONCOLOGY. 2020

  View details for Web of Science ID 000529994300091

• Novel Prognostic Factors in Resected Small Bowel Adenocarcinoma. Clinical colorectal cancer Huffman, B. M., Jin, Z., Yadav, S., Patel, S., Nagorney, D. M., Truty, M. J., McWilliams, R. R., Halfdanarson, T. R., Mahipal, A. 2019; 18 (3): 218-225

  Abstract

  Small bowel adenocarcinoma (SBA) is a rare malignancy affecting approximately 3000 patients per year in the United States, and there is limited evidence prognosticating patients with resected SBA. We aimed to evaluate prognostic factors and the role of adjuvant therapy in patients with resected SBA.Two hundred forty-one patients who had resected stage I-III SBA were retrospectively identified at a single tertiary referral institution. Overall survival (OS) analysis was performed by the Kaplan-Meier method, and Wilcoxon tests were used for statistical comparisons. Cox proportional hazards were performed to identify significant variables by univariate and multivariate analysis.Median OS for the entire group was 54.5 months (95% confidence interval [CI], 37.2-81.2 months), with 5- and 10-year OS of 48% and 35%. Median follow-up was 113.7 months (95% CI, 97.9-126.6 months). For patients with stage III disease who received adjuvant therapy, the median OS was 33.8 months (95% CI, 27.8-78.8) compared to 24.7 months (95% CI, 11.5-37.8) for patients with no adjuvant therapy (P < .01). Male sex, advanced T stage, advanced N stage, increased positive lymph node ratio, lymphocyte-to-monocyte ratio < 1.56, presence of residual disease, and earlier date of diagnosis predicted worse survival on univariate analysis. Age > 60 years, lymphocyte-to-monocyte ratio < 1.56, and advanced T stage were identified as independent negative predictors of OS for all patients by multivariate analysis.Advanced age, advanced T stage, and lymphocyte-to-monocyte ratio < 1.56 independently predicted survival in resected SBA. Adjuvant therapy is associated with improved survival in patients with resected stage III SBA.

  View details for DOI 10.1016/j.clcc.2019.05.002

  View details for PubMedID 31178274

• Validation of lymphocyte to monocyte ratio in resected small bowel adenocarcinoma as a predictor of survival Huffman, B. M., Jin, Z., Yadav, S., Patel, S., Mahipal, A., Halfdanarson, T. AMER SOC CLINICAL ONCOLOGY. 2019

  View details for DOI 10.1200/JCO.2019.37.15_suppl.e15799

  View details for Web of Science ID 000487345801438

• Lymphocyte-to-monocyte ratio and neutrophil-to-lymphocyte ratio independently predict survival in resected small bowel adenocarcinoma. Huffman, B. M., Patel, S., Yadav, S., Jin, Z., Mahipal, A. AMER SOC CLINICAL ONCOLOGY. 2019

  View details for DOI 10.1200/JCO.2019.37.4_suppl.426

  View details for Web of Science ID 000489107600454